DK2696690T3 - Sulfatsalte til forbedring af transittid - Google Patents
Sulfatsalte til forbedring af transittid Download PDFInfo
- Publication number
- DK2696690T3 DK2696690T3 DK12770690.1T DK12770690T DK2696690T3 DK 2696690 T3 DK2696690 T3 DK 2696690T3 DK 12770690 T DK12770690 T DK 12770690T DK 2696690 T3 DK2696690 T3 DK 2696690T3
- Authority
- DK
- Denmark
- Prior art keywords
- sulfate
- oral
- approx
- patient
- administered
- Prior art date
Links
- 150000003467 sulfuric acid derivatives Chemical class 0.000 title claims description 22
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 107
- 239000002775 capsule Substances 0.000 claims abstract description 96
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 37
- 238000001839 endoscopy Methods 0.000 claims abstract description 26
- 230000007170 pathology Effects 0.000 claims abstract description 25
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 26
- 210000001072 colon Anatomy 0.000 claims description 20
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 16
- 229910052920 inorganic sulfate Inorganic materials 0.000 claims description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 13
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 13
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 12
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 12
- 235000011151 potassium sulphates Nutrition 0.000 claims description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 12
- 235000011152 sodium sulphate Nutrition 0.000 claims description 12
- 239000008141 laxative Substances 0.000 claims description 11
- 230000002496 gastric effect Effects 0.000 claims description 10
- 208000011231 Crohn disease Diseases 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 230000002475 laxative effect Effects 0.000 claims description 9
- 230000003902 lesion Effects 0.000 claims description 9
- 230000003204 osmotic effect Effects 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- 239000011591 potassium Substances 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 8
- 230000000740 bleeding effect Effects 0.000 claims description 7
- 210000000813 small intestine Anatomy 0.000 claims description 7
- 208000037062 Polyps Diseases 0.000 claims description 6
- 238000002052 colonoscopy Methods 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000014997 Crohn colitis Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000007784 diverticulitis Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims 10
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 claims 4
- 239000001120 potassium sulphate Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 abstract description 47
- 238000000034 method Methods 0.000 abstract description 34
- 238000010926 purge Methods 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 6
- 239000000243 solution Substances 0.000 description 64
- 208000032843 Hemorrhage Diseases 0.000 description 10
- -1 but not limited to Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 7
- 239000000969 carrier Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 235000015424 sodium Nutrition 0.000 description 5
- 239000001488 sodium phosphate Substances 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- 235000011008 sodium phosphates Nutrition 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000008143 stimulant laxative Substances 0.000 description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940084343 fleet phospho-soda Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 3
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 3
- 244000025596 Cassia laevigata Species 0.000 description 3
- 235000006693 Cassia laevigata Nutrition 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000005744 arteriovenous malformation Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229940124513 senna glycoside Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- UJIDKYTZIQTXPM-UHFFFAOYSA-N [4-[pyridin-2-yl-(4-sulfooxyphenyl)methyl]phenyl] hydrogen sulfate Chemical compound C1=CC(OS(=O)(=O)O)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OS(O)(=O)=O)C=C1 UJIDKYTZIQTXPM-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229960000503 bisacodyl Drugs 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 235000012254 magnesium hydroxide Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- RGPGEMGZZATIQL-UHFFFAOYSA-H magnesium;dipotassium;disodium;trisulfate Chemical compound [Na+].[Na+].[Mg+2].[K+].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RGPGEMGZZATIQL-UHFFFAOYSA-H 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000032953 Device battery issue Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940052354 dibasic sodium phosphate heptahydrate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940056944 golytely Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 235000014659 low sodium diet Nutrition 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000008147 saline laxative Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000002579 sigmoidoscopy Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/04—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/04—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
- A61B1/041—Capsule endoscopes for imaging
Claims (15)
1. Anvendelse af en oral sulfatopløsning til at forberede en patients mavetarmkanal for at undersøge indersiden af patientens mavetarmkanal ved hjælp af kapselendoskopi, hvilken orale sulfatopløsning skal administreres til patienten i en mængde, der er effektiv til at rense patientens mavetarmkanal for dets indhold og til at rengøre mavetarmkanalen og hvilken orale sulfatopløsning er en transithastighedsforstærker, der omfatter natriumsulfat, kaliumsulfat og magnesiumsulfat, omfatter ca. 0,0096 g/ml til ca. 0,50 g/ml sulfat i form af et uorganisk sulfatsalt og som ikke indeholder et phosphat salt.
2. Anvendelsen ifølge krav 1, hvor den orale sulfatopløsning omfatter ca. 0,0095 g/ml til ca. 0,038 g/ml natrium, ca. 0,002 g/ml til ca. 0,009 g/ml kalium, ca. 0,0005 g/ml til ca. 0,05 g/ml magnesium, og ca. 0,02 g/ml til ca. 0,1 g/ml sulfat.
3. Anvendelsen ifølge krav 1, hvor den orale sulfatopløsning omfatter ca. 0,022 g/ml natrium, ca. 0,005 g/ml kalium, ca. 0,001 g/ml magnesium og ca. 0,07 g/ml sulfat.
4. Anvendelse ifølge krav 2 eller krav 3, hvor ca. 15 ml til ca. 1000 ml af den orale sulfatopløsning skal administreres.
5. Anvendelsen ifølge krav 1, hvor den orale sulfatopløsning skal administreres med et kapselendoskop, eller hvor den orale sulfatopløsning skal administreres efter administration af kapselendoskopet eller hvor den orale sulfatopløsning skal administreres mere end én gang før administrationen af kapselendoskopet eller hvor yderligere et osmotisk afføringsmiddel også skal administreres, og det osmotiske afføringsmiddel skal administreres før administration af den orale sulfatopløsning og et kapselendoskop.
6. Anvendelse af en oral sulfatopløsning til at forberede en patients mavetarmkanal for at bestemme kilden, typen, placeringen og årsagen til en gastrointestinal patologi hos patienten, hvilken oral sulfatopløsning skal administreres til patienten, der oplever patologien for at forberede patientens mavetarmkanal til kapsel-koloskopi, hvilken oral sulfatopløsning skal administreres i en mængde, som er effektiv til at udtømme mavetarmkanalen og for at rense mavetarmkanalen, og hvor opløsningen omfatter magnesiumsulfat, kaliumsulfat og natriumsulfat, omfatter ca. 0,0096 g/ml til 0,50 g/ml sulfat i form af et uorganisk sulfatsalt og ikke indeholder et phosphatsalt.
7. Anvendelsen ifølge krav 6, hvor den orale sulfatopløsning omfatter ca. 0,0095 g/ml til ca. 0,038 g/ml natrium, ca. 0,002 g/ml til ca. 0,009 g/ml kalium, ca. 0,0005 g/ml til ca. 0,05 g/ml magnesium, og ca. 0,02 g/ml til ca. 0,1 g/ml sulfat.
8. Anvendelsen ifølge krav 7, hvor den orale sulfatopløsning omfatter ca. 0,022 g/ml natrium, ca. 0,005 g/ml kalium, ca. 0,001 g/ml magnesium og ca. 0,07 g/ml sulfat.
9. Anvendelsen ifølge krav 6, hvor 15 ml til 1000 ml af den orale sulfatopløsning skal administreres.
10. Anvendelsen ifølge krav 6, hvor den orale sulfatopløsning skal administreres med kapselendoskopet eller hvor den orale sulfatopløsning skal administreres før indgivelsen af kapselendoskopet eller hvor den orale sulfatopløsning skal indtages mere end én gang før administration af kapselendoskopet eller hvor et osmotisk afføringsmiddel også skal administreres, og det osmotiske afføringsmiddel skal administreres før administration af den orale sulfatopløsning og et kapselendoskop.
11. Anvendelse ifølge et hvilket som helst af kravene 6-10, hvor den gastrointestinale patologi er en blødning, et sår, en polyp, en læsion, en precancerøs læsion, en cancer, en diverticulitis eller en inflammatorisk lidelse, der indbefatter Crohns sygdom, colitis eller ulcerøst colitis.
12. Anvendelsen ifølge krav 1, hvor undersøgelsen af det indre af patientens mavetarmkanal ved hjælp af kapselendoskopi omfatter at indgive et aktiveret kapselendoskop til patienten oralt; at positionere en modtager for at detektere data, der transmitteres fra det aktiverede kapselendoskop, når det passerer gennem det indre af patientens mavetarmkanal; og at analysere de data, der er detekteret af modtageren før og/eller efter det administrerede kapselendoskop er blevet udstødt fra patientens tyktarm.
13. Anvendelsen ifølge krav 6, hvor bestemmelse af kilden, typen, placeringen og årsagen til den gastrointestinale patologi i patienten omfatter at administrere et aktiveret kapselendoskop til patienten oralt; at positionere en modtager til at detektere og gemme data, der overføres fra kapselendoskopet, når det passerer gennem patientens mavetarmkanal; og at analysere de data, der er detekteret af modtageren før og/eller efter det administrerede kapselendoskop er blevet udstødt fra patientens tyktarm, hvilke data angiver typen, placeringen og årsagen til patologien.
14. Anvendelse af en oral sulfatopløsning til at forberede en patients mavetarmkanal til kapselendoskopi, hvor den orale sulfatopløsning omfatter magnesiumsulfat, kaliumsulfat og natriumsulfat, omfatter ca. 0,0096 g/ml til 0,50 g/ml sulfat i form af et uorganisk sulfatsalt og ikke indeholder et phosphatsalt.
15. Anvendelse af en oral sulfatopløsning til at forøge gastrointestinal eller tyndtarmtransporthastighed for kapselendoskopi, hvor den orale sulfatopløsning omfatter magnesiumsulfat, kaliumsulfat og natriumsulfat, omfatter ca. 0,0096 g/ml til 0,50 g/ml sulfat i form af et uorganisk sulfatsalt og ikke indeholder et phosphatsalt.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161475938P | 2011-04-15 | 2011-04-15 | |
PCT/US2012/033769 WO2012142572A1 (en) | 2011-04-15 | 2012-04-16 | Sulfate salts as transit time enhancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2696690T3 true DK2696690T3 (da) | 2018-01-15 |
Family
ID=47006899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12770690.1T DK2696690T3 (da) | 2011-04-15 | 2012-04-16 | Sulfatsalte til forbedring af transittid |
Country Status (17)
Country | Link |
---|---|
US (1) | US20120265011A1 (da) |
EP (2) | EP3292763A1 (da) |
JP (4) | JP2014513085A (da) |
CY (1) | CY1119693T1 (da) |
DK (1) | DK2696690T3 (da) |
ES (1) | ES2652490T3 (da) |
HK (1) | HK1252468A1 (da) |
HR (1) | HRP20171853T1 (da) |
HU (1) | HUE037452T2 (da) |
LT (1) | LT2696690T (da) |
NO (1) | NO2629082T3 (da) |
PL (1) | PL2696690T3 (da) |
PT (1) | PT2696690T (da) |
RS (1) | RS56574B1 (da) |
RU (3) | RU2013150330A (da) |
SI (1) | SI2696690T1 (da) |
WO (1) | WO2012142572A1 (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS59667B1 (sr) | 2013-03-15 | 2020-01-31 | Braintree Laboratories Inc | Oralna farmaceutska kompozicija sulfatnih soli u obliku tableta dvostruke primene i postupci njihove upotrebe |
CN107787223A (zh) * | 2015-06-22 | 2018-03-09 | 西梯茜生命工学股份有限公司 | 肠道清洁用泻剂组合物 |
US10143656B1 (en) | 2017-08-04 | 2018-12-04 | Braintree Laboratories, Inc. | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
KR102111094B1 (ko) * | 2018-06-18 | 2020-05-14 | 주식회사 한국팜비오 | 무수황산나트륨, 황산칼륨, 무수황산마그네슘 및 시메티콘을 포함하는 장관하제 경구투여용 고형제제 조성물 |
JP6826695B2 (ja) * | 2018-12-10 | 2021-02-03 | 日本製薬株式会社 | 医薬組成物 |
CN110339158B (zh) * | 2019-08-21 | 2020-11-13 | 扬子江药业集团上海海尼药业有限公司 | 一种硫酸钠钾镁口服溶液及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL143259A (en) * | 2001-05-20 | 2006-08-01 | Given Imaging Ltd | A method of moving a bone in the colon |
US6946149B2 (en) * | 2002-04-30 | 2005-09-20 | Braintree Laboratories, Inc. | Salt solution for colon cleansing |
US20050171418A1 (en) * | 2004-01-08 | 2005-08-04 | Tah-Yeong Lin | Capsule endoscopy system |
CN1284505C (zh) * | 2004-02-28 | 2006-11-15 | 重庆金山科技(集团)有限公司 | 医用无线电胶囊式内窥系统 |
RU165065U1 (ru) * | 2015-07-01 | 2016-09-27 | Общество с ограниченной ответственностью "Мобильная Информатика" (ООО "Мобильная Информатика") | Беспроводная эндоскопическая капсула |
-
2012
- 2012-04-16 SI SI201231171T patent/SI2696690T1/en unknown
- 2012-04-16 US US13/447,846 patent/US20120265011A1/en not_active Abandoned
- 2012-04-16 RS RS20171166A patent/RS56574B1/sr unknown
- 2012-04-16 DK DK12770690.1T patent/DK2696690T3/da active
- 2012-04-16 EP EP17194383.0A patent/EP3292763A1/en not_active Withdrawn
- 2012-04-16 JP JP2014505397A patent/JP2014513085A/ja active Pending
- 2012-04-16 LT LTEP12770690.1T patent/LT2696690T/lt unknown
- 2012-04-16 ES ES12770690.1T patent/ES2652490T3/es active Active
- 2012-04-16 EP EP12770690.1A patent/EP2696690B1/en active Active
- 2012-04-16 WO PCT/US2012/033769 patent/WO2012142572A1/en active Application Filing
- 2012-04-16 PT PT127706901T patent/PT2696690T/pt unknown
- 2012-04-16 HU HUE12770690A patent/HUE037452T2/hu unknown
- 2012-04-16 RU RU2013150330/14A patent/RU2013150330A/ru unknown
- 2012-04-16 PL PL12770690T patent/PL2696690T3/pl unknown
-
2013
- 2013-02-15 NO NO13155419A patent/NO2629082T3/no unknown
-
2016
- 2016-03-14 JP JP2016049105A patent/JP6189463B2/ja active Active
-
2017
- 2017-01-30 RU RU2017102973A patent/RU2655886C1/ru active
- 2017-08-02 JP JP2017149775A patent/JP6356324B2/ja not_active Expired - Fee Related
- 2017-11-28 HR HRP20171853TT patent/HRP20171853T1/hr unknown
- 2017-12-19 CY CY20171101333T patent/CY1119693T1/el unknown
-
2018
- 2018-05-22 RU RU2018118808A patent/RU2018118808A/ru not_active Application Discontinuation
- 2018-06-13 JP JP2018112399A patent/JP6782281B2/ja active Active
- 2018-09-13 HK HK18111776.7A patent/HK1252468A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
HK1252468A1 (zh) | 2019-05-24 |
HUE037452T2 (hu) | 2018-08-28 |
US20120265011A1 (en) | 2012-10-18 |
JP6189463B2 (ja) | 2017-08-30 |
RS56574B1 (sr) | 2018-02-28 |
EP2696690A4 (en) | 2014-10-29 |
ES2652490T3 (es) | 2018-02-02 |
JP6356324B2 (ja) | 2018-07-11 |
CY1119693T1 (el) | 2018-04-04 |
JP2017200948A (ja) | 2017-11-09 |
PT2696690T (pt) | 2017-12-22 |
NO2629082T3 (da) | 2018-03-31 |
HRP20171853T1 (hr) | 2018-02-23 |
PL2696690T3 (pl) | 2018-03-30 |
LT2696690T (lt) | 2018-02-12 |
EP3292763A1 (en) | 2018-03-14 |
EP2696690A1 (en) | 2014-02-19 |
JP2018145197A (ja) | 2018-09-20 |
RU2655886C1 (ru) | 2018-05-29 |
EP2696690B1 (en) | 2017-10-04 |
SI2696690T1 (en) | 2018-03-30 |
RU2018118808A (ru) | 2019-11-25 |
JP6782281B2 (ja) | 2020-11-11 |
JP2014513085A (ja) | 2014-05-29 |
JP2016155833A (ja) | 2016-09-01 |
RU2013150330A (ru) | 2015-05-20 |
WO2012142572A1 (en) | 2012-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6356324B2 (ja) | 通過時間エンハンサーとしての硫酸塩 | |
CN103338768B (zh) | 胃和结肠的配制剂及其制备和使用方法 | |
US20100297264A1 (en) | Bowel purgative and uses thereof | |
Mans | Clinical update on diagnosis and management of disorders of the digestive system of reptiles | |
EP1976520B1 (en) | Kit comprising an osmotic laxative and a stimulant laxative for preparing the colon for virtual colonoscopy | |
Mans et al. | Update on diseases of chinchillas | |
US9375441B2 (en) | Lactulose for bowel evacuation | |
JP2013516390A (ja) | 緩下作用がある電解質及び炭水化物を含むエネルギー性栄養組成物 | |
US20160279166A1 (en) | Treating agent and treating method for the examination or operation of the large intestine | |
CA2725125A1 (en) | Colon cleansing method and kit | |
Franke et al. | Prospective evaluation of small bowel preparation with bisacodyl and sodium phosphate for capsule endoscopy | |
Landeras et al. | Virtual colonoscopy: technique and accuracy | |
US10124074B2 (en) | Indirect chromoendoscopy with an oral indigo carmine base preparation | |
JP5696326B2 (ja) | Ctコロノグラフィ検査用医薬 | |
Ward | Rodents: digestive system disorders | |
Andersen et al. | Increased intestinal permeability for the isosmolar contrast medium iodixanol during small-bowel ischaemia in rats | |
Defarges | " Endoscopy on the go": how videocapsule endoscopy put the complete gut at anybody's reach. | |
Ortner et al. | Small bowel involvement in Crohn’s disease | |
Manire | Basic clinical medicine for stranded cetaceans. | |
JPS649291B2 (da) | ||
Bhatnagar et al. | Anirudha M. Gopanpallikar Prabha Sawant Pravin Rathi Chodankar CM | |
Whelchel et al. | Case Reporteve_82 451.. 455 |